Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EXAGEN INC. (XGN)

Exagen Q3 revenue rises 7% to $18.4 million as net loss narrows to $6.3 million

Positive Impact 3 of 5 earnings

Exagen reported third-quarter 2026 revenue of $18.4 million, up 7% from $17.2 million a year earlier, and a net loss of $6.3 million, compared with $7.1 million in the prior-year quarter. The company reiterated its full-year 2026 revenue guidance of $72 million to $75 million, which means results did not change its outlook.

Key points

  • Q3 2026 revenue $18.4 million vs. $17.2 million in Q3 2025; nine-month revenue $55.7 million, up 11%
  • Q3 2026 net loss $6.3 million vs. $7.1 million; nine-month net loss $13.5 million vs. $15.3 million
  • Full-year 2026 revenue guidance of $72 million to $75 million reiterated; cash and equivalents $28.1 million at September 30, 2026

The filing

CompanyEXAGEN INC. (XGN)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:33 AM ET
Accession number0001274737-26-000063

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:45 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.